ARK Investment Management LLC increased its stake in shares of Compugen by 108.2% in the fourth quarter.

Source: https://www.americanbankingnews.com/2023/03/01/compugen-ltd-expected-to-earn-fy2027-earnings-of-0-44-per-share-nasdaqcgen.html

Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors.

Source: https://www.prnewswire.com/news-releases/compugen-reports-fourth-quarter-and-full-year-2022-results-301756395.html

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.

Source: https://www.dailypolitical.com/2023/01/08/compugen-nasdaqcgen-now-covered-by-analysts-at-ef-hutton-acquisition-co-i.html

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.

Source: https://www.dailypolitical.com/2023/01/08/compugen-nasdaqcgen-now-covered-by-analysts-at-ef-hutton-acquisition-co-i.html